CathRx, Ltd. appears in FDA premarket notification records as the applicant for Khelix diagnostic electrophysiology catheters, a Class II electrode recording catheter line under product code DRF and regulation 21 CFR 870.1220. The most recent supplied record is K262068 for the Khelix Magnetic Sensor Electrophysiology Catheter (SS1-*-*-MAG), received June 22, 2026 and decided October 9, 2026 as substantially equivalent. The supplied collection holds one linked record, and that single record carries a substantially equivalent decision. [1][2][7]

The magnetic sensor catheter filing

K262068 covers the Khelix Magnetic Sensor Electrophysiology Catheter (SS1-*-*-MAG), filed as a Traditional 510(k) with a summary, reviewed by the Cardiovascular panel and not by a third party. The applicant address in the filing is Unit 8, 2-8 S. St., Rydalmere, Australia, with the applicant contact listed as Henry Le. The decision description is Substantially Equivalent, dated October 9, 2026. [1][2]

The FDA record classifies the device as Catheter, Electrode Recording, Or Probe, Electrode Recording, device class 2, regulation number 870.1220, medical specialty Cardiovascular. The same classification and product code appear on the earlier Khelix clearance, which supports reading the magnetic sensor device as part of the same electrode recording catheter category rather than a separate device type. [1][6]

Earlier Khelix clearance

K211327, received May 3, 2021 and decided February 10, 2022, covered Khelix Steerable Electrophysiology Catheters, Khelix Loop Fixed Electrophysiology Catheters, Khelix Fixed Loop Steerable Electrophysiology Catheters and Khelix Variable Loop Steerable Electrophysiology Catheters. The decision was Substantially Equivalent under the same regulation and product code, reviewed by the Cardiovascular panel and not by a third party. [6][7]

The K211327 summary identifies the trade name as Khelix Diagnostic Electrophysiology Catheters, lists CathRx Ltd at the Rydalmere address, and names the US agent and correspondent as Acorn N Oakes, LLC. It also lists Ian Fong as CathRx Chief Executive Officer. These are filing roles, not evidence of ownership of any other entity. [7]

Portfolio as the company describes it

CathRx's own site describes a diagnostic catheter portfolio organized into Khelix Loop EP Catheters, Khelix Steerable EP Catheters and Khelix Fixed EP Catheters, positioned for both ablation and diagnostic procedures. The company states that its diagnostic catheter portfolio holds regulatory approvals across major markets, without specifying which markets or which variants in the public information. [3]

The steerable catheter page states that Khelix Steerable catheters are unidirectional, controlled by a push/pull knob on the handle, and offered in different curve shapes and electrode configurations. It states that they are approved as single-use devices and that certain variants are also approved for reuse, described as reposable up to ten times, and that they are available in CE Mark countries. [5]

CathRx describes itself as based in Sydney, Australia, working on electrophysiology diagnostics and therapeutic pulsed-field ablation, with a stated mission concerning atrial fibrillation and hypertension. Its products page lists the ElectroPulse PFA System as an investigational device not available for sale. [4][8]

What the linked FDA records do not establish

The supplied collection contains one linked 510(k) record, K262068, and that record's decision is substantially equivalent; this is a snapshot of the supplied filings, not a measure of total company sales, total portfolio or safety performance. No recall records are supplied. The K211327 record appears in the numbered sources but is not part of the linked collection count. [1][6]

No parent company, brand ownership, customer list or commercial availability for the magnetic sensor catheter is documented in the public documents. The Rydalmere address appears as the applicant address in FDA filings and as the company address on CathRx's site; it is not treated here as a verified headquarters designation beyond what those publishers state. [1][3][7]